Prostate Cancer Clinical Trial
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Summary
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry.
The patient population will be separated into two cohorts:
Cohort A: Patients with poor response to prior abiraterone defined as:
Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: < 12 months duration on abiraterone or failure to achieve PSA nadir of 0.2 ng/mL while taking abiraterone, or;
Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: < 6 months duration on abiraterone or failure to achieve PSA50 response while on abiraterone
Cohort B: Patients with response to prior abiraterone, defined as:
Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: ≥ 12 months duration on abiraterone and nadir PSA < 0.2 ng/mL, or;
Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: ≥ 6 months duration on abiraterone and confirmed PSA50 response
Eligibility Criteria
Inclusion Criteria:
Males age ≥ 18 years
Metastatic, castration-resistant, histologically confirmed prostate cancer
Surgical castration or continuous medical castration for ≥ 8 weeks prior to screening; serum testosterone < 50 ng/dL confirmed within 4 weeks of first administration of study drug
Have progressed on prior abiraterone treatment by PCWG3 criteria
Patients who are not candidates for chemotherapy in the opinion of the investigator or patients who decline chemotherapy
Cohort A only - Patient must meet definition of poor responder to abiraterone by one of the following:
Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: < 12 months duration on abiraterone or failure to achieve PSA nadir of 0.2 ng/mL while taking abiraterone
Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: < 6 months duration on abiraterone or failure to achieve a PSA50 response
Cohort B only - Patient must meet definition of responder to abiraterone by one of the following:
Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: ≥ 12 months duration on abiraterone and nadir PSA < 0.2 ng/mL
Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: ≥ 6 months duration on abiraterone and PSA50 response
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria:
Any history of brain metastases, prior seizure, conditions predisposing to seizure activity
Have previously received an investigational BET inhibitor (including previous participation in this study or a study of ZEN003694)
Receipt of prior second-generation androgen receptor inhibitors (e.g. enzalutamide, apalutamide, darolutamide, proxalutamide). Receipt of first-generation AR antagonists (e.g. bicalutamide, nilutamide, flutamide) does not count towards this limit.
Have received prior chemotherapy in the metastatic castration-resistant setting (prior chemotherapy in the hormone-sensitive setting is allowed provided last dose was at least 6 months prior to first dose of study drug)
Have received prior systemic anti-cancer therapy within 2 weeks or five half-lives, whichever is shorter, prior to the first administration of study drug
Have received exogenous administration of testosterone therapy since discontinuation of abiraterone.
Failure to recover to Grade 1 or lower toxicity related to prior systemic therapy (excluding alopecia and neuropathy) prior to study entry
Radiation therapy within 2 weeks of the first administration of study drug
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 24 Locations for this study
San Francisco California, 94158, United States
Whittier California, 90603, United States
Lakewood Colorado, 80228, United States
Plantation Florida, 33322, United States
Baton Rouge Louisiana, 70809, United States
Ann Arbor Michigan, 48109, United States
New York New York, 10065, United States
Asheville North Carolina, 28806, United States
Seattle Washington, 98109, United States
Hefei Anhui, 23000, China
Chongqing Chongqing, 40003, China
Xiamen Fujian, 36100, China
Zhengzhou Henan, 45000, China
Wuhan Hubei, 43003, China
Wuhan Hubei, 43007, China
Changsha Hunan, 41000, China
Nanjing Jiangsu, 21000, China
Shenyang Liaoning, 11004, China
Xi'an Shaanxi, 71000, China
Shanghai Shanghai, 20003, China
Shanghai Shanghai, 20007, China
Taiyuan Shanxi, 03000, China
Chengdu Sichuan, 61007, China
Hangzhou Zhejiang, 31001, China
How clear is this clinincal trial information?